Chiusura precedente | 0,3840 |
Aperto | 0,3910 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 0,3790 - 0,3910 |
Intervallo di 52 settimane | 0,2600 - 0,8690 |
Volume | |
Media Volume | 68.467 |
Capitalizzazione | 209.552 |
Beta (5 anni mensile) | 0,86 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,2150 |
Prossima data utili | N/D |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
NEWS RELEASE – REGULATED INFORMATION JUNE 5, 2023, 5:30 pm ET/ 23:30 CEST MDxHealth Announces its Extraordinary General Shareholders’ Meeting IRVINE, CA, and HERSTAL, BELGIUM – June 5, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today invites the holders of securities issued by the Company to its extraordinary general shareholders' meeting that will be held on Friday, June 30, 2023 at 9:00 a.m., Belgia
NEWS RELEASE - REGULATED INFORMATION 25 May 2023, 22:30 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a commercial-stage precision diagnostics company, today held its ordinary annual general shareholders' meeting ("AGM") and an extraordinary general shareholders' meeting ("EGM"). The items on the agenda of the AGM incl
NEWS RELEASEMay 23, 2023, 4PM ET/ 22:00 CET MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference IRVINE, CA, and HERSTAL, BELGIUM – May 23, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael McGarrity, Chief Executive Officer, will present at William Blair’s 43rd Annual Growth Stock Conference on Thursday, June 8, 2023, at 1:00pm ET. A live webcast of the presentation will be available
NEWS RELEASE - REGULATED INFORMATION15 MAY 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Q1-2023 Results Year-over-year revenues increase by 141% to $14.7 million; excluding GPS, revenues up 39% Gross margin expanded by 1,270 basis points over prior year periodPositive Local Coverage Determination (LCD), extending coverage for Select mdx test to Medicare population IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics co
NEWS RELEASE 1 MAY 2023, 4PM ET / 22:00 CET MDxHealth to Present First Quarter 2023 Financial Results on May 15 Company to Host Conference Call with Live Q&A, May 15, 2023 at 4:30pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2023, after market close on Monday, May 15, 2023. Title:MDxHealth Presents
NEWS RELEASE – REGULATED INFORMATIONAPRIL 25, 2023, 4:00 pm ET/ 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM – April 25, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today invites the holders of securities issued by the Company to its ordinary and extraordinary general shareholders' meetings that will be held on Thursday, May 25, 2023 at 3:00 p.m., Belgian time. The items on the agenda of the ordinary and
NEWS RELEASE – INSIDE INFORMATIONApril 19, 2023, 4:00PM EDT / 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM – April 19, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, received notice that its Select mdx for Prostate Cancer test has successfully completed a rigorous technical assessment process with the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA. Select mdx will be reimbursed throughout the U.S. for Medicare patients who m
NEWS RELEASE – REGULATED INFORMATION APRIL 7, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – April 7, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the
NEWS RELEASE 13 MARCH 2023, 2:00 AM ET / 08:00 CET IRVINE, CA, and HERSTAL, BELGIUM – March 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today confirms that neither MDxHealth SA, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank. About mdxhealth Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatme
NEWS RELEASE – REGULATED INFORMATIONMARCH 8, 2023, 5:00 pm ET/ 23:00 CET IRVINE, CA, and HERSTAL, BELGIUM – March 8, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context o
NEWS RELEASE - REGULATED INFORMATION8 MARCH 2023, 4:00 PM EST / 22:00 CET Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 8, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided a business update and outlook for 2023. Highlights for the fourth quarter and yea
NEWS RELEASE – REGULATED INFORMATION MARCH 6, 2023, 5:30 pm ET/ 23:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that, in the context of the registered public offering of 10,000,000 American Depositary Shares (“ADSs”) (each representing 10 ordinary shares of the Company without nominal value) previously announced and completed on February 7, 2023 (the
NEWS RELEASE – REGULATED INFORMATION MARCH 3, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 3, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "
NEWS RELEASEFEBRUARY 28, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 28, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael McGarrity, chief executive officer, will present at Cowen’s 43rd Annual Health Care Conference on Monday, March 6th, 2023 at 1:30pm ET. A live webcast of the presentation will be available on the Company’s website. Cowen’s 43rd Annual Health Care Conference is t
NEWS RELEASEFEBRUARY 22, 2023, 4:30pm ET/ 22:30 CET Company to Host Conference Call with Live Q&A, March 8, 2023 at 4:30pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 22, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2022, after market close on Wednesday, March 8, 2023. Title:Mdxhea
NEWS RELEASE – REGULATED INFORMATIONFEBRUARY 15, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 15, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the c
NEWS RELEASE 13 FEBRUARY 2023, 4:00PM ET / 22:00 CET UnitedHealthcare singles out mdxheath’s GPS test as its only commercially-covered test to risk stratify men newly diagnosed with localized prostate cancer IRVINE, CA, and HERSTAL, BELGIUM – February 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that UnitedHealthcare will cover the mdxhealth Genomic Prostate Score (GPS) test (formerly Oncotype DX GPS) under UnitedHealthcare’s
NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET MDxHealth Announces Pricing of Offering of ADSsin the United States IRVINE, CA, and HERSTAL, BELGIUM – February 3, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 10,000,000 American Depositary Shares (“ADSs”) (each representing 10 ordinary shares of the Compan
NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 1, 2023, 4PM ET/ 22:00 CET MDxHealth Announces Launch of Offering of ADSs in the United States IRVINE, CA, and HERSTAL, BELGIUM –February 1, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40,000,000 of American Depositary Shares ("ADSs") (each representing 10 ordinary shares of the Company without nominal val
NEWS RELEASE –REGULATED INFORMATION20 JANUARY 2023, 1:00 am ET / 7:00 am CET MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test IRVINE, CA, and HERSTAL, BELGIUM – January 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided supplemental information related to its acquisition of the Oncotype DX® GPS (Genomic Prostate Score®) test on August 2, 2022 (the “GPS Test Acquisition”), from Genom
NEWS RELEASE – INSIDE AND REGULATED INFORMATION9 JANUARY 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary 2022 revenues and reaffirmed its 2023 revenue guidance. The Company expects to report 2022 revenues of approximately $37 million, with a year-end cash balance of $15.5 mi
NEWS RELEASE – REGULATED INFORMATIONDecember 19, 2022, 5:00PM EDT / 23:00 CET Mdxhealth files U.S. Shelf Registration on Form F-3 IRVINE, CA, and HERSTAL, BELGIUM – December 19, 2022 – Mdxhealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that it has filed a U.S. “shelf” registration statement for its American Depositary Shares (“ADSs”), each representing 10 ordinary shares. The Company filed the shelf registration statement and associated financ
NEWS RELEASE – INSIDE AND REGULATED INFORMATION29 NOVEMBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Provides Business Update IRVINE, CA, and HERSTAL, BELGIUM – November 29, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided clinical and reimbursement product developments, updated guidance for 2022, and initial guidance for 2023. Select mdx reimbursement update Under the foundational LCD (Local Coverage Decision) process recently implemente
NEWS RELEASE - REGULATED INFORMATION27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL, BELGIUM – October 27, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for the third quarter ended September 30, 2022. Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report continued strong operating results for the third quarter 2022. Our focus on operating
NEWS RELEASE - REGULATED INFORMATION25 AUGUST 2022, 4:00PM EDT, 22:00 CET MDxHealth Reports Half Year 2022 Results IRVINE, CA, and HERSTAL, BELGIUM – August 25, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announced its financial results for the half year ended June 30, 2022. Michael K. McGarrity, CEO of mdxhealth, commented: “We are excited to report strong operating results for the first half of 2022, couple